Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis.

Curtis JR, Flake DD 2nd, Weinblatt ME, Shadick NA, Østergaard M, Hetland ML, Brahe CH, Hwang YG, Furst DE, Strand V, Etzel CJ, Pappas DA, Wang X, Hwang CC, Sasso EH, Gutin A, Hitraya E, Lanchbury JS.

Rheumatology (Oxford). 2018 Dec 24. doi: 10.1093/rheumatology/key367. [Epub ahead of print]

PMID:
30590790
2.

The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.

Roodenrijs NMT, de Hair MJH, Wheater G, Elshahaly M, Tekstra J, Teng YKO, Lafeber FPJG, Hwang CC, Liu X, Sasso EH, van Laar JM.

Arthritis Res Ther. 2018 Nov 20;20(1):256. doi: 10.1186/s13075-018-1750-5.

3.

Predictive value of a multi-biomarker disease activity score for clinical remission and radiographic progression in patients with early rheumatoid arthritis: a post-hoc study of the OPERA trial.

Brahe CH, Østergaard M, Johansen JS, Defranoux N, Wang X, Bolce R, Sasso EH, Ørnbjerg LM, Hørslev-Petersen K, Stengaard-Pedersen K, Junker P, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll C, Jørgensen A, Krintel SB, Raun J, Hetland ML.

Scand J Rheumatol. 2019 Jan;48(1):9-16. doi: 10.1080/03009742.2018.1464206. Epub 2018 Jul 9.

PMID:
29985080
4.

Multi-biomarker disease activity score as a predictor of disease relapse in patients with rheumatoid arthritis stopping TNF inhibitor treatment.

Ghiti Moghadam M, Lamers-Karnebeek FBG, Vonkeman HE, Ten Klooster PM, Tekstra J, Schilder AM, Visser H, Sasso EH, Chernoff D, Lems WF, van Schaardenburg DJ, Landewe R, Bernelot Moens HJ, Radstake TRDJ, van Riel PLCM, van de Laar MAFJ, Jansen TL; Dutch National POET Collaboration.

PLoS One. 2018 May 23;13(5):e0192425. doi: 10.1371/journal.pone.0192425. eCollection 2018.

5.

A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.

Bouman CAM, van der Maas A, van Herwaarden N, Sasso EH, van den Hoogen FHJ, den Broeder AA.

Rheumatology (Oxford). 2017 Jun 1;56(6):973-980. doi: 10.1093/rheumatology/kex003.

PMID:
28339738
6.
7.

Investigation of a multi-biomarker disease activity score in rheumatoid arthritis by comparison with magnetic resonance imaging, computed tomography, ultrasonography, and radiography parameters of inflammation and damage.

Krabbe S, Bolce R, Brahe CH, Døhn UM, Ejbjerg BJ, Hetland ML, Sasso EH, Chernoff D, Hansen MS, Knudsen LS, Hansen A, Madsen OR, Hasselquist M, Møller J, Østergaard M.

Scand J Rheumatol. 2017 Sep;46(5):353-358. doi: 10.1080/03009742.2016.1211315. Epub 2016 Sep 28.

PMID:
27682742
8.

Association of a multibiomarker disease activity score at multiple time-points with radiographic progression in rheumatoid arthritis: results from the SWEFOT trial.

Hambardzumyan K, Bolce RJ, Saevarsdottir S, Forslind K, Wallman JK, Cruickshank SE, Sasso EH, Chernoff D, van Vollenhoven RF.

RMD Open. 2016 Mar 1;2(1):e000197. doi: 10.1136/rmdopen-2015-000197. eCollection 2016.

9.

Multibiomarker disease activity score and C-reactive protein in a cross-sectional observational study of patients with rheumatoid arthritis with and without concomitant fibromyalgia.

Lee YC, Hackett J, Frits M, Iannaccone CK, Shadick NA, Weinblatt ME, Segurado OG, Sasso EH.

Rheumatology (Oxford). 2016 Apr;55(4):640-8. doi: 10.1093/rheumatology/kev388. Epub 2015 Nov 25.

10.

Relationship of multi-biomarker disease activity score and other risk factors with radiographic progression in an observational study of patients with rheumatoid arthritis.

Li W, Sasso EH, van der Helm-van Mil AH, Huizinga TW.

Rheumatology (Oxford). 2016 Feb;55(2):357-66. doi: 10.1093/rheumatology/kev341. Epub 2015 Sep 18.

11.

Does the multi-biomarker disease activity score have diagnostic value in early rheumatoid arthritis and unclassified arthritis?

Maijer KI, Li W, Sasso EH, Gerlag DM, Defranoux NA, Tak PP.

Ann Rheum Dis. 2015 Nov;74(11):2097-9. doi: 10.1136/annrheumdis-2015-207911. Epub 2015 Sep 2. No abstract available.

12.

Brief report: enhancement of patient recruitment in rheumatoid arthritis clinical trials using a multi-biomarker disease activity score as an inclusion criterion.

van Vollenhoven RF, Bolce R, Hambardzumyan K, Saevarsdottir S, Forslind K, Petersson IF, Sasso EH, Hwang CC, Segurado OG, Geborek P.

Arthritis Rheumatol. 2015 Nov;67(11):2855-60. doi: 10.1002/art.39274.

13.

Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis.

Reiss WG, Devenport JN, Low JM, Wu G, Sasso EH.

Rheumatol Int. 2016 Feb;36(2):295-300. doi: 10.1007/s00296-015-3285-2. Epub 2015 May 31.

14.

Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis.

Segurado OG, Sasso EH.

Clin Exp Rheumatol. 2014 Sep-Oct;32(5 Suppl 85):S-29-34. Epub 2014 Oct 30. Review.

PMID:
25365086
15.

A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study.

Markusse IM, Dirven L, van den Broek M, Bijkerk C, Han KH, Ronday HK, Bolce R, Sasso EH, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

J Rheumatol. 2014 Nov;41(11):2114-9. doi: 10.3899/jrheum.131412. Epub 2014 Aug 15.

16.

Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial.

Hambardzumyan K, Bolce R, Saevarsdottir S, Cruickshank SE, Sasso EH, Chernoff D, Forslind K, Petersson IF, Geborek P, van Vollenhoven RF.

Ann Rheum Dis. 2015 Jun;74(6):1102-9. doi: 10.1136/annrheumdis-2013-204986. Epub 2014 May 8.

17.

Impact of a multi-biomarker disease activity test on rheumatoid arthritis treatment decisions and therapy use.

Li W, Sasso EH, Emerling D, Cavet G, Ford K.

Curr Med Res Opin. 2013 Jan;29(1):85-92. doi: 10.1185/03007995.2012.753042. Epub 2012 Dec 14.

PMID:
23176063
18.

Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study.

Papp K, Menter A, Poulin Y, Gu Y, Sasso EH.

J Eur Acad Dermatol Venereol. 2013 May;27(5):634-42. doi: 10.1111/j.1468-3083.2012.04515.x. Epub 2012 Mar 16.

PMID:
22429586
19.

Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.

Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH.

J Am Acad Dermatol. 2012 Feb;66(2):241-51. doi: 10.1016/j.jaad.2010.12.005. Epub 2011 Jul 14.

PMID:
21752491
20.

Relationship between methotrexate dosing and clinical response in patients with moderate to severe psoriasis: subanalysis of the CHAMPION study.

Saurat JH, Langley RG, Reich K, Unnebrink K, Sasso EH, Kampman W.

Br J Dermatol. 2011 Aug;165(2):399-406. doi: 10.1111/j.1365-2133.2011.10399.x. Epub 2011 Jul 11.

PMID:
21564071
21.

Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.

Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH.

Arthritis Res Ther. 2010;12(3):R113. doi: 10.1186/ar3049. Epub 2010 Jun 10.

22.

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.

Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, Sasso EH.

J Rheumatol. 2009 Jul;36(7):1429-41. doi: 10.3899/jrheum.081018. Epub 2009 Apr 15. Erratum in: J Rheumatol. 2010 Oct;37(10):2198. J Rheumatol. 2010 May;37(5):1081.

PMID:
19369462
23.

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.

Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian DK, Salfeld J, Sasso EH.

Clin Immunol. 2009 May;131(2):308-16. doi: 10.1016/j.clim.2009.01.002. Epub 2009 Feb 1.

PMID:
19188093
24.

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.

Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP.

Pharmacol Ther. 2008 Feb;117(2):244-79. Epub 2007 Oct 26. Review.

PMID:
18155297
25.

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.

Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH; M02-570 Study Group.

J Rheumatol. 2007 May;34(5):1040-50. Epub 2007 Apr 15. Erratum in: J Rheumatol. 2007 Jun;34(6):1439.

PMID:
17444593
26.

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH.

Arthritis Rheum. 2007 Feb;56(2):476-88.

27.

Frequent joining of Bcl-2 to a JH6 gene in hepatitis C virus-associated t(14;18).

Sasso EH, Martinez M, Yarfitz SL, Ghillani P, Musset L, Piette JC, Cacoub P.

J Immunol. 2004 Sep 1;173(5):3549-56.

28.
29.
30.

Effect of 51p1-related gene copy number (V1-69 locus) on production of hepatitis C-associated cryoglobulins.

Sasso EH, Ghillani P, Musset L, Piette JC, Cacoub P.

Clin Exp Immunol. 2001 Jan;123(1):88-93.

31.
32.

Hereditary resistance to activated protein C: an uncommon risk factor for thromboembolic disease in lupus patients with antiphospholipid antibodies.

Sasso EH, Suzuki LA, Thompson AR, Petri MA.

Arthritis Rheum. 1997 Sep;40(9):1720-1. No abstract available.

PMID:
9324029
33.

Expression of an Ig VH gene, 51p1, is proportional to its germline gene copy number.

Sasso EH, Johnson T, Kipps TJ.

Ann N Y Acad Sci. 1997 Apr 5;815:478-80. No abstract available.

PMID:
9186703
34.

Hepatitis C virus and rheumatic disease.

Wener MH, Johnson RJ, Sasso EH, Gretch DR.

J Rheumatol. 1996 Jun;23(6):953-9. Review. No abstract available.

PMID:
8782121
35.

Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number.

Sasso EH, Johnson T, Kipps TJ.

J Clin Invest. 1996 May 1;97(9):2074-80.

36.

Ethnic differences in VH gene polymorphism.

Sasso EH, Buckner JH, Suzuki LA.

Ann N Y Acad Sci. 1995 Sep 29;764:72-3. No abstract available.

PMID:
7486592
37.

Ethnic differences of polymorphism of an immunoglobulin VH3 gene.

Sasso EH, Buckner JH, Suzuki LA.

J Clin Invest. 1995 Sep;96(3):1591-600.

38.

The structural basis of germline-encoded VH3 immunoglobulin binding to staphylococcal protein A.

Hillson JL, Karr NS, Oppliger IR, Mannik M, Sasso EH.

J Exp Med. 1993 Jul 1;178(1):331-6.

39.

A fetally expressed immunoglobulin VH1 gene belongs to a complex set of alleles.

Sasso EH, Willems van Dijk K, Bull AP, Milner EC.

J Clin Invest. 1993 Jun;91(6):2358-67.

40.

Chromosomal organization of the human VH4 gene family. Location of individual gene segments.

van der Maarel S, van Dijk KW, Alexander CM, Sasso EH, Bull A, Milner EC.

J Immunol. 1993 Apr 1;150(7):2858-68.

PMID:
8454861
41.

Emerging human B cell repertoire. Influence of developmental stage and interindividual variation.

Hillson JL, Oppliger IR, Sasso EH, Milner EC, Wener MH.

J Immunol. 1992 Dec 1;149(11):3741-52.

PMID:
1331240
42.

Immunoglobulin V genes in rheumatoid arthritis.

Sasso EH.

Rheum Dis Clin North Am. 1992 Nov;18(4):809-36. Review.

PMID:
1455046
43.

Chromosomal organization of the heavy chain variable region gene segments comprising the human fetal antibody repertoire.

Willems van Dijk K, Milner LA, Sasso EH, Milner EC.

Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10430-4.

44.

VH genes in tandem array comprise a repeated germline motif.

Sasso EH, Willems van Dijk K, Bull A, van der Maarel SM, Milner EC.

J Immunol. 1992 Aug 15;149(4):1230-6.

PMID:
1500714
45.

Human IgA and IgG F(ab')2 that bind to staphylococcal protein A belong to the VHIII subgroup.

Sasso EH, Silverman GJ, Mannik M.

J Immunol. 1991 Sep 15;147(6):1877-83.

PMID:
1909733
46.

Polymorphism of the human Ig VH4 gene family.

van Dijk KW, Sasso EH, Milner EC.

J Immunol. 1991 May 15;146(10):3646-51.

PMID:
1673987
47.

Prevalence and polymorphism of human VH3 genes.

Sasso EH, Van Dijk KW, Milner EC.

J Immunol. 1990 Oct 15;145(8):2751-7.

PMID:
1976703
48.

Human IgM molecules that bind staphylococcal protein A contain VHIII H chains.

Sasso EH, Silverman GJ, Mannik M.

J Immunol. 1989 Apr 15;142(8):2778-83.

PMID:
2495325
49.
50.

Rheumatoid factors in immune complexes of patients with rheumatoid arthritis.

Mannik M, Nardella FA, Sasso EH.

Springer Semin Immunopathol. 1988;10(2-3):215-30. Review. No abstract available.

PMID:
3055378

Supplemental Content

Loading ...
Support Center